We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

FN:NYSEFabrinet Analysis

Data as of 2026-06-22 - not real-time

$573.76

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Fabrinet is trading around $573, well below its 52‑week high but still far above the DCF‑derived fair value of roughly $207. The stock sits under its 20‑day and 50‑day moving averages, indicating a short‑term downtrend. A bearish MACD crossover and a negative histogram reinforce the momentum weakness. The 14‑day RSI hovers near the 40‑level, suggesting limited upside momentum. Volume has been tapering, and the market’s “Extreme Greed” sentiment may be overstating expectations. Consequently, the technical picture points to a cautious near‑term stance.
On the fundamentals side, revenue surged 39% YoY and margins remain modest but positive, supporting a growth narrative. ROE approaches 20% and debt is minimal, though free cash flow is currently negative. The valuation multiples (P/E ~49, P/B ~9) are well above industry averages, flagging overvaluation. High 30‑day volatility (~85%) and a computed beta above 2 signal pronounced market sensitivity. Geographic exposure across North America, APAC and Europe adds medium geographic risk. Overall, the profile suggests a hold for the medium term with a potential upside if valuation compresses over the longer horizon.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 6/10

Key Factors

  • Price below 20‑day and 50‑day SMAs
  • Bearish MACD crossover
  • Decreasing volume and high volatility

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Strong revenue growth and ROE
  • Minimal debt but negative free cash flow
  • Valuation still above fair value

Long Term

> 3 years
Positive
Model confidence: 6/10

Key Factors

  • Sustained top‑line growth in high‑tech optical market
  • Robust balance sheet with low leverage
  • Potential valuation compression as market sentiment normalizes

Key Metrics & Analysis

Financial Health

Revenue Growth39.30%
Profit Margin9.94%
P/E Ratio49.2
ROE19.99%
ROA8.52%
Debt/Equity0.19
P/B Ratio8.9
Op. Cash Flow$256.9M
Free Cash Flow$-79178376
Industry P/E38.1

Technical Analysis

TrendNeutral
RSI40.5
Support$550.03
Resistance$732.63
MA 20$642.32
MA 50$663.83
MA 200$510.84
MACDBearish
VolumeDecreasing
Fear & Greed Index91.46

Valuation

Fair Value$206.96
Target Price$749.11
Upside/Downside30.56%
GradeOvervalued
TypeGrowth

Risk Assessment

Beta2.82
Volatility85.12%
Sector RiskHigh
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.